BlackRock, Inc. Reduces Stake in Oruka Therapeutics, Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, disclosing a reduction in its stake in Oruka Therapeutics, Inc. As of the snapshot date of October 17, 2025, BlackRock, Inc. holds 2,197,517 shares, representing a 4.5% ownership in the company. This marks a decrease of 2,841,565 shares, or 56.39%, from its previous holdings. The filing indicates that BlackRock, Inc. has sole voting power over 2,149,266 shares and sole dispositive power over all 2,197,517 shares. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.